Cancer immunotherapy
FDA-approved antibodies

Antibody
Brand name
Type
Target
Approval date
Approved treatment(s)
Alemtuzumab
Campath
humanized
CD52
2001
B-cell chronic lymphocytic leukemia (CLL)
Atezolizumab
Tecentriq
humanized
PD-L1
2016
bladder cancer
Avelumab
Bavencio
human
PD-L1
2017
metastatic Merkel cell carcinoma
Ipilimumab
Yervoy
human
CTLA4
2011
metastatic melanoma
Ofatumumab
Arzerra
human
CD20
2009
refractory CLL
Nivolumab
Opdivo
human
PD-1
2014
unresectable or metastatic melanoma, squamous non-small cell lung cancer, Renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, classical hodgkin lymphoma
Pembrolizumab
Keytruda
humanized
PD-1
2014
unresectable or metastatic melanoma, squamous non-small cell lung cancer (NSCLC), Hodgkin's lymphoma, Merkel-cell carcinoma (MCC), primary mediastinal B-cell lymphoma (PMBCL), stomach cancer, cervical cancer
Rituximab
Rituxan, Mabthera
chimeric
CD20
1997
non-Hodgkin lymphoma
Durvalumab
Imfinzi
human
PD-L1
2017
bladder cancer non-small cell lung cancer

Question: What is Ofatumumab used for?
Answer: The Ofatumumab is a human antibody that binds to CD20.